Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab, Tremelimumab, and Fulvestrant in HR+ HER2- Metastatic Breast Cancer
NCT03430466Phase 2Terminated
- Sponsor
- Kyoto Breast Cancer Research Network
- Start
- Jun 2017
- Primary completion
- Jan 2018
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in breast cancer, sponsored by Kyoto Breast Cancer Research Network. Started Jun 2017; status: terminated.
02
Drugs
durvalumabtremelimumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03430466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03430466.